Peripheral blood cellular dynamics of Rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs.. Peripheral blood cellular dynamics of Rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs.

Samples from healthy blood donors, newly diagnosed RA patients, and established RA patients that had an inadequate response to MTX and were about to start tumor necrosis factor inhibitors (TNFi) treatment were collected before and after 3 months treatment. We used in parallel a computational deconvolution approach based on RNA expression and flow cytometry to determine the relative cell-type frequencies Overall design: We included 53 DMARD treatment naïve early RA patients, 37 individuals who previously did not responded to MTX treatment and started TNFi treatment, and 30 age matched healthy controls at two timepoints separated by approximately 3 months. Data was pooled into 10 groups into each cohort ***Submitter declares that European law does not allow the deposit of the raw data to GEO***

本研究采集了健康献血者、新诊断类风湿关节炎（RA, Rheumatoid Arthritis）患者，以及经甲氨蝶呤（MTX, Methotrexate）治疗应答不佳、即将启动肿瘤坏死因子抑制剂（TNFi, Tumor Necrosis Factor Inhibitors）治疗的确诊RA患者的外周血样本，采集时间覆盖治疗前及治疗3个月后。我们并行采用基于RNA表达谱与流式细胞术的计算反卷积方法，以确定细胞类型的相对占比。总体实验设计：本研究纳入53例未接受过改善病情抗风湿药（DMARD, Disease-Modifying Antirheumatic Drugs）治疗的早期RA患者、37例既往经MTX治疗应答不佳并启动TNFi治疗的RA患者，以及30例年龄匹配的健康对照，所有样本均采集于间隔约3个月的两个时间点。本研究将各队列的数据合并为10个组别。***提交者声明：根据欧盟法律，无法将原始数据提交至基因表达综合数据库（GEO, Gene Expression Omnibus）***